You can view the research column published every month by SMC Laboratories.
2025.02.02
Drug Efficacy Studies in NASH Mouse Model
Today, we would like to introduce a study published by our client, Tsumura, in which they used our pre-clinica…
READ MORE
2025.02.02
In-vivo screening and pharmacology study for liver cancer
We would like to introduce an in-vivo screening study using our liver orthotopic xenograft and STAM™ models. I…
READ MORE
2025.02.02
Pre-clinical studies for Liver Cancer: STAM model
For Today’s topic, I would like to focus on Hepatocellular Carcinoma (HCC). We have summarized the chara…
READ MORE
2025.02.02
Characterization of a lung fibrosis model and its usefulness
We offer the Idiopathic Pulmonary Fibrosis (IPF) model as a potential model for the development of therapeutic…
READ MORE
2025.02.02
Interesting relevance between liver cancer patients and our cancer mouse model
Do you have any interest in liver cancer, hepatocellular carcinoma (HCC), or doing research about HCC? We hope…
READ MORE
2025.02.02
STAM mice develop NASH-derived hepatocarcinoma
Last year, the following article was even published in Nature Reviews Gastroenterology & Hepatology. Globa…
READ MORE
2025.02.02
Combination Therapies for NASH
It is now accepted that many factors are involved in exacerbating the NASH pathophysiology such as lipotoxicit…
READ MORE
2025.02.02
Pre-clinical studies for NASH: CDAHFD mice model
Today, we would like to give you a brief introduction to the choline-deficient, L-amino acid-defined, high-fat…
READ MORE
2025.02.02
Case study of preclinical studies for NASH
Among our lineup is the STAM™ model, which is our proprietary model that shows a 100% progression rate from NA…
READ MORE
2025.02.02
Drug Efficacy Studies in Custom Model_ Muscular Dystrophy Mouse Model
In order to meet the diversifying needs of our clients, we often use our years of expertise conducting preclin…
READ MORE
